Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS)

Ian Mitchell, Mahwesh Saleem, Abby Li, Monica Ruff, Krista Lanctot, Bosco Paes
European Respiratory Journal 2019 54: PA1006; DOI: 10.1183/13993003.congress-2019.PA1006
Ian Mitchell
1University of Calgary, Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: imitche@ucalgary.ca
Mahwesh Saleem
2University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Abby Li
2University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monica Ruff
1University of Calgary, Calgary, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krista Lanctot
2University of Toronto, Toronto, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bosco Paes
3Mcmaster University, Hamilton, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: CARESS, Canadian palivizumab usage registry, tracks utilization & respiratory illnesses. Individual clinicians decide on palivizumab use.

Aims: To provide information on management and outcome of children given palivizumab, whatever the indications; to inform on real life use; to track changes in practice over time.

Design: The registry enrols children from 37 sites in Canada who receive >1 dose of palivizamab. Data collected monthly.

Results: 25,003 children were enrolled from 2005 to 2017. Average age at enrolment was 5.7 ± 6.4 months old; mean gestational age of 32.6 ± 5.0 weeks.1724 children were hospitalized 2054 times, overall respiratory illness-related hospitalization (RIH) rate was 6.9%. The lowest rate of hospitalization was in preterm infants (4.3%) .1474 of 1724 were tested for RSV, and 334 children were RSV-positive, a cumulative RSV-positive hospitalization rate (RSVH) of 1.6%. Indications for palivizumab changed over time. Percentage of those with Bronchopulmonary dysplasia/Chronic Lung Disease remained in the range 10.6-8.8% while premature fell from 74.4% to 66/1%, congenital heart disease peaked at 12.5% 2013-15. Usage in the “other” group (medical complexity) rose from 5.6% to 22.6% (2013-15). The numbers (&%) with specific diagnoses were: Trisomy 21 942 (21.2), Congenital airway anomaly 855 (19.2), Neurological disorders 471 (10.6), Cystic fibrosis 442 (9.9) other pulmonary 438 (9.8). The remainder were children with multiple indications, or individually less common diseases.

Conclusions: Palivizamab is effective in many groups of infants as shown by the comparison of RSVH versus RIH. Palivizumab use increased over time in children with medical complexity.

  • Children
  • Bronchiolitis
  • Viruses

Footnotes

Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA1006.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2019
Previous
Back to top
Vol 54 Issue suppl 63 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS)
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS)
Ian Mitchell, Mahwesh Saleem, Abby Li, Monica Ruff, Krista Lanctot, Bosco Paes
European Respiratory Journal Sep 2019, 54 (suppl 63) PA1006; DOI: 10.1183/13993003.congress-2019.PA1006

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
An assessment of the use of palivizumab over 12 years from a Canadian Registry (CARESS)
Ian Mitchell, Mahwesh Saleem, Abby Li, Monica Ruff, Krista Lanctot, Bosco Paes
European Respiratory Journal Sep 2019, 54 (suppl 63) PA1006; DOI: 10.1183/13993003.congress-2019.PA1006
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Parents' attitude towards seasonal vaccination of children against an influenza virus
  • Structured Light Plethysmography (SLP) in COVID-19 children with acute respiratory symptoms
  • Reopening of schools and pediatric ER admissions during SARS-CoV-2 pandemic in Italy
Show more Paediatric respiratory infection and immun.

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society